Pharmaceutical Technology on MSN
Harbour BioMed and BMS sign multi-specific antibody collab
Harbour is eligible for payments of $90m, with potential development and commercial milestones of up to $1.035bn.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback